Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 18/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.67 |
| ▸ | RAF1 | P04049 | 1/20 | 0.62 |
| ▸ | SRC | P12931 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL593645 | 0.92 | TNK2 (0.85) | TNK2FGFR1RAF1SRC | |
| SCHEMBL12165303 | 0.89 | TNK2 (0.80) | TNK2FGFR1RAF1SRC | |
| SCHEMBL593475 | 0.84 | TNK2 (0.72) | TNK2FGFR1RAF1SRC | |
| Hydrochloric Acid SCHEMBL594350 | 0.83 | TNK2 (0.71) | TNK2FGFR1RAF1SRC | |
| SCHEMBL2462683 | 0.83 | TNK2 (0.83) | TNK2 | |
| SCHEMBL4356359 | 0.82 | TNK2 (1.00) | TNK2 | |
| SCHEMBL8181452 | 0.82 | RAF1 (0.75) | TNK2FGFR1RAF1SRC | |
| SCHEMBL593343 | 0.82 | IGF1R (0.75) | TNK2FGFR1RAF1SRC | |
| SCHEMBL593344 | 0.82 | IGF1R (0.75) | TNK2FGFR1RAF1SRC | |
| SCHEMBL593994 | 0.81 | PIK3CA (0.76) | TNK2FGFR1RAF1SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8481733-B2 | Substituted imidazopyr- and imidazotri-azines | OSI Pharmaceuticals, LLC (US) | 2013-07-09 | — | — | US | disclosed |
| US-8481733-B2 | Substituted imidazopyr- and imidazotri-azines | OSI Pharmaceuticals, LLC (US) | 2013-07-09 | — | — | US | disclosed |
| US-8481733-B2 | Substituted imidazopyr- and imidazotri-azines | OSI Pharmaceuticals, LLC (US) | 2013-07-09 | — | — | US | disclosed |
| US-20090286768-A1 | SUBSTITUTED IMIDAZOPYR- AND IMIDAZOTRI-AZINES | OSI PHARMACEUTICALS, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| US-20090286768-A1 | SUBSTITUTED IMIDAZOPYR- AND IMIDAZOTRI-AZINES | OSI PHARMACEUTICALS, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| US-20090286768-A1 | SUBSTITUTED IMIDAZOPYR- AND IMIDAZOTRI-AZINES | OSI PHARMACEUTICALS, INC. (US) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286768-A1 | SUBSTITUTED IMIDAZOPYR- AND IMIDAZOTRI-AZINES | ABL1, TPMT, CYP2C19 | TNK2 2837/4885FGFR1 163/4885RAF1 970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.